Abstract.
Cyclooxygenases (COX-1 and COX-2) catalyze the conversion of arachidonic acid to prostaglandins (PGs). PGs play a significant role in bone metabolism in health and disease. Conventional non-selective, non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXIBs) are widely used in patients with musculoskeletal conditions and as a post-surgical analgesics. Due to their effects on PG synthesis, these drugs have been hypothesized to affect the healing process of bone fractures and orthopedic surgical sites. A variety of experimental models of bone, ligament, and tendon repair have assessed the effects of these selective and non-selective COX inhibitors in animals, but with variable outcomes. At this time, large-scale, robust clinical study data do not exist, limiting the relevant assessment of experimental animal data to humans. Here, we provide a critical review of available data on the role of PGs and the effect of COX inhibitors on bone, tendon, and ligament repair. Collectively, this assessment suggests potential involvement of PGs in the healing process of these tissues via modulation by non-selective NSAIDs and selective COX-2 inhibitors.
Article PDF
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Additional information
Received 25 April 2005; returned for revision 9 June 2005; accepted by G. Geisslinger 10 June 2005
Rights and permissions
About this article
Cite this article
Radi, Z.A., Khan, N.K. Effects of cyclooxygenase inhibition on bone, tendon, and ligament healing. Inflamm. res. 54, 358–366 (2005). https://doi.org/10.1007/s00011-005-1367-4
Issue Date:
DOI: https://doi.org/10.1007/s00011-005-1367-4